Drug · CHEMBL3286830
LORLATINIB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LORLATINIB. Drugs and targets, record CHEMBL3286830. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3286830
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 16 diseases, from ATC, DailyMed, EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ALK | ALK tyrosine kinase receptor | ALK tyrosine kinase receptor inhibitor | INHIBITOR | https://conductscience.org/library/genes/238 |
| ALK | EML4-ALK | EML4-ALK inhibitor | INHIBITOR | https://conductscience.org/library/genes/238 |
| EML4 | EML4-ALK | EML4-ALK inhibitor | INHIBITOR | https://conductscience.org/library/genes/27436 |
Source ChEMBL
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| non-small cell lung carcinoma | Approval | DailyMed, EMA Human Drugs, FDA, PMDA and TTD | 47 | 41 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| lung adenocarcinoma | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005061 |
| lung cancer | Phase 1/2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0008903 |
| neuroblastoma | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005072 |
| cancer | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| diffuse intrinsic pontine glioma | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006033 |
| diffuse midline glioma | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0020983 |
| ganglioneuroblastoma | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005035 |
| hematopoietic and lymphoid cell neoplasm | Phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0044881 |
| malignant glioma | Early phase 1 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0100342 |
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials65
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | Phase 1/2 | 364 | 2018-05-29 | pf-06463922 | Its name | ClinicalTrials.gov |
| NCT03052608 | A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | Phase 3 | 296 | 2021-04-01 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT03909971 | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | Phase 2 | 109 | 2021-10-26 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | Phase 4 | 100 | 2024-12-20 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT04362072 | Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer | Phase 4 | 71 | 2025-06-11 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT03107988 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | Phase 1 | 65 | 2025-09-15 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | Phase 1/2 | 43 | 2022-02-09 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT03542305 | Lorlatinib Renal Impairment Study | Phase 1 | 29 | 2021-02-21 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT02804399 | A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers | Phase 1 | 12 | 2019-01-25 | lorlatinib | Its name | ClinicalTrials.gov |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | Phase 2 | 10 | 2023-11-21 | lorlatinib | Its name | ClinicalTrials.gov |
1 to 10 of 65
See all 65 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause | 364 of 618 | 3,780 of 4,661 | 5,279 | NCT05834348 | Trial comparisons |
| Lorlatinib vs Crizotinib: deaths from any cause | 23 of 149 | 28 of 142 | 291 | NCT03052608 | Trial comparisons |
| Lorlatinib vs Crizotinib: serious adverse events | 51 of 149 | 39 of 142 | 291 | NCT03052608 | Trial comparisons |
| Lorlatinib vs Crizotinib: Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage | 2 of 143 | 1 of 133 | 276 | NCT03052608 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 28 of 67 | 26 of 42 | 109 | NCT03909971 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 23 of 67 | 16 of 42 | 109 | NCT03909971 | Trial comparisons |
| Lorlatinib 2L vs Lorlatinib 3L or Later: Number of Participants With Anaplastic Lymphoma Kinase (ALK) Test Result | 29 of 29 | 22 of 22 | 51 | NCT04979988 | Trial comparisons |
| Lorlatinib 2L vs Lorlatinib 3L or Later: Number of Participants for Whom Dates of ALK Test Was Available | 29 of 29 | 22 of 22 | 51 | NCT04979988 | Trial comparisons |
| Group A: Avelumab + Crizotinib vs Group B: Avelumab + Lorlatinib: deaths from any cause | 10 of 12 | 15 of 31 | 43 | NCT02584634 | Trial comparisons |
| Group A: Avelumab + Crizotinib vs Group B: Avelumab + Lorlatinib: serious adverse events | 5 of 12 | 21 of 31 | 43 | NCT02584634 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials49
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42872552 | DERIVED | 1 | PubMed |
| 42781551 | DERIVED | 1 | PubMed |
| 42749050 | DERIVED | 1 | PubMed |
| 41986720 | DERIVED | 1 | PubMed |
| 41949116 | DERIVED | 1 | PubMed |
| 41296331 | DERIVED | 1 | PubMed |
| 41124598 | DERIVED | 1 | PubMed |
| 40541556 | DERIVED | 1 | PubMed |
| 40024442 | DERIVED | 1 | PubMed |
| 39863139 | DERIVED | 1 | PubMed |
1 to 10 of 49
See all 49 papers from its trialsTests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Choice Reaction Time | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 0 | ConductCognition |
| 2-Back Task | 1 | 0 | ConductCognition |
| Simple Reaction Time | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3286830
GET https://conductscience.org/api/drugs/v1/CHEMBL3286830/trials?page=2